Physician profile
Steven M Shaw
NPI 1881841492
$2,587.00
in general payments reported to CMS, 2019-2025
20 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $541 · 2020: $368 · 2021: $302 · 2022: $388 · 2023: $283 · 2024: $604 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $987.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $686.44 | 2019-2025 | Total30, Tryptyr, Precision 1 |
| Maculogix, INC. | $334.33 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $221.04 | 2023-2025 | Infuse, Miebo, Alden Scleral Zenlens |
| Biotissue Holdings INC. | $216.88 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $204.73 | 2020-2023 | |
| Shire North American Group INC | $177.48 | 2019 | |
| Optos, INC. | $122.32 | 2019-2021 | |
| Oyster Point Pharma, INC. | $107.53 | 2022-2025 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $106.57 | 2020-2022 | |
| Harrow Eye, LLC | $79.23 | 2024 | Vevye |
| Coopervision INC. | $74.80 | 2022-2024 | Myday Contact Lens |
| Dompe US, INC. | $54.39 | 2022-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $52.99 | 2021-2024 | Cequa |
| Kala Pharmaceuticals, INC. | $36.31 | 2021-2022 | |
| Notal Vision, INC. | $27.03 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $25.17 | 2024 | Xdemvy |
| Sight Sciences, INC. | $19.26 | 2022 | |
| Allergan, INC. | $17.85 | 2022 | |
| Spark Therapeutics, INC. | $13.20 | 2022 | |
| Abb Con-Cise Optical Group LLC | $9.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.